title: Comparison of efficacy of products containing azelaic acid in melasma treatment.
abstract: BACKGROUND
  Melasma is one of the most frequently diagnosed hyperpigmentation changes on the skin of women's faces. Nearly 30% of women using oral estrogen therapy struggle with this problem. A common way of reducing melasma is the application of azelaic acid products.
  
  
  OBJECTIVE
  Comparison of efficacy of three dermocosmetic products, containing azelaic acid, in the reduction in melasma for women aged 35-55.
  
  
  METHODS
  A group of 60 women diagnosed with melasma were divided into three even, twenty-person subgroups. Each subgroup was assigned one dermocosmetic product containing azelaic acid. For 24 weeks, the patients applied the assigned product twice a day. The level of the colorant within the hyperpigmentation was marked before the treatment, after 1 month, after 3 months, and after 6 months of therapy. The pigmentation was measured using Mexameter(®) (Courage + Khazaka electronic, Germany). In addition, during each inspection, the patients' level of hydration, elasticity, and intensity of erythema was checked using Corneometer(®) , Reviscometer(®) .
  
  
  RESULTS
  All dermocosmetics containing azelaic acid that were applied significantly contributed to the reduction in pigment in the pigmentary lesion. The largest decrease in the amount of pigment was observed in the first 3 months of use of the products. A combination containing 20% azelaic acid and mandelic acid, phytic acid, 4N-butyl resorcinol, and ferulic acid proved to be the most effective dermocosmetic III (Sesderma, Valencia, Spain).
  
  
  CONCLUSIONS
  Dermocosmetics containing azelaic acid significantly contribute to the clearing of melasma. The effect depends on the treatment time, the acid concentration, and addition of other components.
authors.affiliation: Department of Aesthetic Medicine, Chair of Cosmetology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Katowice, Poland.
authors.forename: Klaudia
authors.initials: K
authors.lastname: Mazurek
authors.affiliation: Department of Aesthetic Medicine, Chair of Cosmetology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Katowice, Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Pierzchała
mesh_terms: D000328:Adult; D000068937:Cosmeceuticals / Q000737:chemistry* / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000032:analysis / Q000627:therapeutic use*; D003998:Dicarboxylic Acids / Q000032:analysis / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008333:Mandelic Acids / Q000627:therapeutic use; D008548:Melanosis / Q000188:drug therapy*; D008875:Middle Aged; D010833:Phytic Acid / Q000627:therapeutic use; D012118:Resorcinols / Q000627:therapeutic use; D013997:Time Factors
chemical_list: C508220:4-n-butylresorcinol; D000068937:Cosmeceuticals; D003879:Dermatologic Agents; D003998:Dicarboxylic Acids; D004338:Drug Combinations; D008333:Mandelic Acids; D012118:Resorcinols; D010833:Phytic Acid; C010038:azelaic acid; C037938:mandelic acid
keywords: azelaic acid; cosmeceutical; melasma